Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/12/2021 (updated 4/10/2024)
64,000 people died from an overdose in the U.S. in 2016. Fentanyl-related deaths are up 540% in the last 3 years. In 2016 72% of the 1,374 fatal overdoses in NYC involved heroin and/or fentanyl
Posted 10/23/2020 (updated 4/3/2024)
The American Society of Addiction Medicine (ASAM) developed this National Practice Guideline for the Treatment of Opioid Use Disorder to provide information on evidence-based treatment of opioid use disorder.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 11/20/2023 (updated 3/28/2024)
The U.S. Food and Drug Administration cleared the use of Alltest Fentanyl Urine Test Cassette, which is the first over-the-counter test for the preliminary detection of fentanyl in urine. The test works by placing three drops of fresh urine onto a cassette containing a fentanyl test strip. After 5 minutes the test result will appear as colored lines. Although the test does not distinguish between certain drugs and medications.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.